Back
ProShares Ultra Nasdaq Biotechnology Vs. Sarepta Therapeutics Industry Stock Comparison
Sell
46
BIB
ProShares Ultra Nasdaq Biotechnology
Last Price:
59.65
Seasonality Move:
10.34%
Buy
58
SRPT
Sarepta Therapeutics
Last Price:
133.49
Seasonality Move:
14.88%
Sell
46
ProShares Ultra Nasdaq Biotechnology (BIB)
is a Sell
Is ProShares Ultra Nasdaq Biotechnology a Buy, Sell or Hold?
- The current ProShares Ultra Nasdaq Biotechnology [BIB] share price is $59.53. The Score for BIB is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.
- BIB is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
58
Sarepta Therapeutics (SRPT)
is a Buy
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $133.34. The Score for SRPT is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.
- SRPT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
BIB Stock Price Chart
What is ProShares Ultra Nasdaq Biotechnology's stock price today?
-
The ProShares Ultra Nasdaq Biotechnology share price today is $59.53
The current trend is relatively stagnant and BIB is experiencing selling pressure, which indicates risk of future bearish movement.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $133.34
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing selling pressure, which indicates risk of future bearish movement.
BIB Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -1.32 | Sell |
| Relative Strength Index (14 RSI): | 48.99 | Sell |
| Chaikin Money Flow: | -4483 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (56.31 - 64.21) | Sell |
| Bollinger Bands (100): | (60.15 - 66.99) | Sell |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.78 | Buy |
| Relative Strength Index (14 RSI): | 63.54 | Buy |
| Chaikin Money Flow: | -725343 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (110.85 - 129.81) | Buy |
| Bollinger Bands (100): | (119.21 - 141.67) | Buy |
BIB Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 56.98 | Buy |
| 20-day SMA: | 59.83 | Sell |
| 50-day SMA: | 61.75 | Sell |
| 200-day SMA: | 59.97 | Sell |
| 8-day EMA: | 58.25 | Buy |
| 20-day EMA: | 59.21 | Buy |
| 50-day EMA: | 61.12 | Sell |
| 200-day EMA: | 60.1 | Sell |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 119.83 | Buy |
| 20-day SMA: | 118.14 | Buy |
| 50-day SMA: | 122.33 | Buy |
| 200-day SMA: | 130.09 | Buy |
| 8-day EMA: | 123.82 | Buy |
| 20-day EMA: | 120.48 | Buy |
| 50-day EMA: | 122.96 | Buy |
| 200-day EMA: | 126.17 | Buy |
ProShares Ultra Nasdaq Biotechnology Earnings Growth & BIB Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.75 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $7.74 per share.
ProShares Ultra Nasdaq Biotechnology Technical Analysis
| Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | Nov 27 | Nov 29 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | 29 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | Nov 27 | Nov 29 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | 29 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||